India  

COVID-19: Govt's expert panel allows clinical trials for third dose of Covaxin

Hindu Friday, 2 April 2021 ()
In the meeting, Bharat Biotech presented amendments in the approved Phase 3 clinical trial protocol.
0
shares
ShareTweetSavePostSend
 

You Might Like


Related videos from verified sources

'COVAXIN' demonstrated efficacy of 80.6% in Phase 3 clinical trial: Bharat Biotech [Video]

'COVAXIN' demonstrated efficacy of 80.6% in Phase 3 clinical trial: Bharat Biotech

Bharat Biotech's COVID-19 vaccine, 'COVAXIN' has demonstrated an interim vaccine efficacy of 80.6% in its Phase 3 clinical trial. "Today is an important day for us, country and Indian science. COVAXIN..

Credit: ANI     Duration: 01:42Published
See first dose of Johnson & Johnson Covid-19 vaccine being administered [Video]

See first dose of Johnson & Johnson Covid-19 vaccine being administered

The one-dose Johnson & Johnson Covid-19 vaccine is administered in the United States for the first time outside of a clinical trial at a mass vaccination site in Columbus, Ohio.

Credit: Bleacher Report AOL     Duration: 00:43Published
They thought they got the Covid-19 vaccine. They were part of a trial instead [Video]

They thought they got the Covid-19 vaccine. They were part of a trial instead

More than a dozen slum residents in Bhopal, India, say they thought they were being vaccinated for Covid-19. They say they later discovered from local activists that some of them hadn’t been given an..

Credit: Bleacher Report AOL     Duration: 03:42Published